Rare disease drug development funding increased 28% in 2021
According to a new report by the rare disease organization Global Genes, interest in the rare disease space is growing, with a total of $22.9 billion raised by rare disease therapeutic developers in 2021. In 2020, $18 billion was raised.
“Rare diseases continue to have a strong allure to investors, as evidenced by the significant capital raised in 2021 to advance companies and pipelines focused on rare conditions,” said Craig Martin, CEO of Global Genes, in a press release. “We hope and expect that the sector will continue to be strengthened by the vast array of opportunities to advance promising biotechnologies, under expedited review, that can address the tremendous burdens and underlying causes of thousands of rare, genetic conditions currently without approved treatments.”
Read the full press release here.